Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individuals' perceptions and experiences of mHealth for home-based rehabilitation in knee osteoarthritis: A qualitative study.

Osteoarthritis and cartilage open·2026
Same author

Postmenopausal Osteoporosis, Endothelial Dysfunction, and Cardiovascular Risk.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Patient expectations and preferences regarding patient-reported outcome measures in chronic low back pain.

Annals of physical and rehabilitation medicine·2026
Same author

Longitudinal incidence of native septic arthritis in France: a 13-year analysis of the National Health Data System Database.

Rheumatology (Oxford, England)·2026
Same author

Ocrelizumab in a difficult-to-treat rheumatoid arthritis patient.

Clinical and experimental rheumatology·2026
Same author

Prevalence and impact of sleep disorders in osteoarthritis: A systematic review and meta-analysis.

Osteoarthritis and cartilage open·2026

Related Experiment Video

Updated: Jun 12, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Elderly-onset rheumatoid arthritis.

Martin Soubrier1, Sylvain Mathieu, Sarah Payet

  • 1Service de Rhumatologie, hôpital G.-Montpied, BP 69, 63003 Clermont-Ferrand, France. msoubrier@chu-clermontferrand.fr

Joint Bone Spine
|June 18, 2010
PubMed
Summary
This summary is machine-generated.

Treating elderly rheumatoid arthritis (RA) requires managing comorbidities and drug risks. While methotrexate and TNFalpha antagonists show efficacy, careful monitoring for adverse effects in older adults is crucial for controlling disease activity and cardiovascular risks.

More Related Videos

Evaluation of Changes in Hydration and Body Cell Mass with Bioelectrical Impedance Analysis after Exercise Program for Rheumatoid Arthritis Patients
07:44

Evaluation of Changes in Hydration and Body Cell Mass with Bioelectrical Impedance Analysis after Exercise Program for Rheumatoid Arthritis Patients

Published on: July 14, 2023

Related Experiment Videos

Last Updated: Jun 12, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Evaluation of Changes in Hydration and Body Cell Mass with Bioelectrical Impedance Analysis after Exercise Program for Rheumatoid Arthritis Patients
07:44

Evaluation of Changes in Hydration and Body Cell Mass with Bioelectrical Impedance Analysis after Exercise Program for Rheumatoid Arthritis Patients

Published on: July 14, 2023

Area of Science:

  • Rheumatology
  • Geriatric Medicine
  • Clinical Pharmacology

Background:

  • Elderly-onset rheumatoid arthritis (RA) presents unique challenges due to comorbidities and increased susceptibility to adverse drug events.
  • Standard treatment goals for RA include controlling clinical manifestations, preventing structural damage, preserving function, and reducing excess mortality.

Purpose of the Study:

  • To review the therapeutic strategies and challenges in treating rheumatoid arthritis in elderly patients.
  • To evaluate the efficacy and safety of various drug classes, including NSAIDs, corticosteroids, methotrexate, and TNFalpha antagonists, in the elderly RA population.

Main Methods:

  • Review of clinical trials and observational studies on RA treatment in elderly patients.
  • Analysis of data regarding efficacy, safety profiles, and adverse events associated with different therapeutic agents.
  • Examination of registry data for TNFalpha antagonist use in RA.

Main Results:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) carry risks of cardiovascular, gastrointestinal, and renal adverse events.
  • Corticosteroid benefits are offset by significant adverse effects, despite short-term clinical improvements.
  • Methotrexate is effective in elderly patients with normal renal function, without a higher adverse event rate.
  • Etanercept demonstrated efficacy in reducing disease activity and improving function, with a comparable or slightly higher adverse event rate in older adults versus conventional therapies.
  • Registry data confirm TNFalpha antagonist effectiveness, with some indicating an increased infection rate.

Conclusions:

  • Treatment of elderly RA requires balancing therapeutic benefits against increased risks of adverse events and comorbidities.
  • Stringent control of disease activity and aggressive management of cardiovascular risk factors are essential for combating the elevated cardiovascular risk in RA patients.
  • Methotrexate and TNFalpha antagonists are viable treatment options, necessitating careful patient selection and monitoring.